Vaccinex, Inc.
VCNX
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and pā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.85
Price-28.33%
-$0.33
1Y
Price
Market Cap
$2.264m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1575.1%
EBITDA Margin-1584.0%
Net Profit Margin-1846.0%
Free Cash Flow Margin-1575.1%
EBITDA Margin-1584.0%
Net Profit Margin-1846.0%
Free Cash Flow MarginRevenue
$2.095m
+5.4%
1y CAGR+128.9%
3y CAGR+521.6%
5y CAGREarnings
-$5.260m
+8.0%
1y CAGR+5.7%
3y CAGR+9.9%
5y CAGREPS
-$1.97
+76.0%
1y CAGR+57.1%
3y CAGR+55.2%
5y CAGRBook Value
-$7.591m
$1.799m
Assets$9.390m
Liabilities$5.517m
DebtDebt to Assets
306.7%
-1.1x
Debt to EBITDAFree Cash Flow
-$6.459m
+6.3%
1y CAGR+13.5%
3y CAGR+13.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company